<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04458779</url>
  </required_header>
  <id_info>
    <org_study_id>109018-E</org_study_id>
    <nct_id>NCT04458779</nct_id>
  </id_info>
  <brief_title>CPAP on Acute Stroke and OSA</brief_title>
  <official_title>Cardiovascular Effects of Continuous Positive Airway Pressure in Patients With Acute Stroke and Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Far Eastern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Far Eastern Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke affects 16.9 million individuals each year and is the second leading cause of death&#xD;
      worldwide. Despite advances in pharmacologic therapy, morbidity , mortality and rates of&#xD;
      hospitalization for stroke remain high. These data emphasize the importance of identifying&#xD;
      all treatable conditions that could aggravate stroke. One such condition is obstructive sleep&#xD;
      apnea (OSA).&#xD;
&#xD;
      Sleep-related breathing disorders, including obstructive and central sleep apnea, often&#xD;
      coexist with stroke. Compared to the general population, in whom OSA is the most common form&#xD;
      of this breathing disorder with recent prevalence estimates of 22% of male and 17% of female&#xD;
      , in the stroke population, the prevalence of OSA is much greater at 70% . Several randomized&#xD;
      controlledtrials on OSA patients with stroke in acute or sub-acute stage showed that treating&#xD;
      OSA with continuous positive airway pressure (CPAP) improved motor and functional outcomes,&#xD;
      accelerated neurological recovery.Apart from the benefits in better neurological outcomes,&#xD;
      secondary analyses of SAVE study suggested that CPAP treatment potentially help to reduce&#xD;
      recurrence of stroke. Nevertheless, we don't have evidence yet from randomized control&#xD;
      studies to prove CPAP treatment would reduce the recurrence of cardiovascular or&#xD;
      cerebrovascular events.&#xD;
&#xD;
      Traditionally, recurrence of cardiovascular or cerebrovascular events uses documented&#xD;
      mortality, morbidity or hospitalization for heart failure, acute coronary syndrome or stroke&#xD;
      as clinical endpoints. Recently, several studies showed that enlarged left atrium (LA) can&#xD;
      serve as a predictor for recurrent stroke or cardiovascular events. On the other hand, a&#xD;
      growing body of studies demonstrated that CPAP treatment reduce size of LA in those with OSA.&#xD;
      Notably, all of these studies above are observational or retrospective in nature. To date,&#xD;
      there are no prospective longitudinal randomized controlled trials reporting the effect of&#xD;
      CPAP treatment of OSA on the change of size of LA. We therefore will undertake a randomized ,&#xD;
      controlled trial involving patients with stroke to test the primary hypothesis that treatment&#xD;
      of OSA with CPAP would reduce the size of LA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in left atrium volume index (LAVI)</measure>
    <time_frame>12 months</time_frame>
    <description>Change of LAVI will be assessed by transthoracic echocardiography at baseline and at 3, 6 and 12 months post randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serial change of NT-proBNP</measure>
    <time_frame>12 months</time_frame>
    <description>Change of NT-proBNP will be assessed at baseline and at 3, 6 and 12 months post randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological and functional assessments-1</measure>
    <time_frame>12 months</time_frame>
    <description>Change in National Institutes of Health (NIH) stoke scale will be assessed at baseline ,3, 6 and 12 months post randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological and functional assessments-2</measure>
    <time_frame>12 months</time_frame>
    <description>Change in modified Rankin scale will be assessed at baseline, 3, 6 and 12 months post randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological and functional assessments-3</measure>
    <time_frame>12 months</time_frame>
    <description>Chang in Barthel-ADL index will be assessed at baseline, 3, 6 and 12 months post randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of life assessments</measure>
    <time_frame>12 months</time_frame>
    <description>Change in Epworth sleepiness scale and Medical Outcomes Study 36-Item Short-Form Health Survey at baseline, 3, 6 and 12 months post randomization.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Numbers of cardiovascular or cerebrovascular events</measure>
    <time_frame>12 months</time_frame>
    <description>Numbers of cardiovascular or cerebrovascular events post randomization</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to cardiovascular or cerebrovascular events</measure>
    <time_frame>12 months</time_frame>
    <description>Time to cardiovascular or cerebrovascular events post randomization</description>
  </other_outcome>
  <other_outcome>
    <measure>Numbers of all-cause hospitalizations</measure>
    <time_frame>12 months</time_frame>
    <description>Numbers of hospitalizations for any reason post randomization</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of deaths</measure>
    <time_frame>12 months</time_frame>
    <description>Numbers of deaths from all causes post randomization</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to deaths</measure>
    <time_frame>12 months</time_frame>
    <description>Time to deaths from all causes post randomization</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Stroke, Acute</condition>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>CPAP group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive CPAP treatment in addition to optimal standard therapy for acute stroke.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual-care group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will receive optimal standard therapy for acute stroke.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP</intervention_name>
    <description>CPAP will be given after obstructive sleep apnea being diagnosed in the acute stage of stroke.</description>
    <arm_group_label>CPAP group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Time from onset of stroke symptoms to hospital arrival &lt;2 weeks .&#xD;
&#xD;
          2. Stroke is documented with brain magnetic imaging or computed tomography&#xD;
&#xD;
          3. Competency to provide informed consent.&#xD;
&#xD;
          4. Moderate to severe obstructive sleep apnea being established with the use of a home&#xD;
             sleep-study screening device (ApneaLink).&#xD;
&#xD;
          5. Epworth sleepiness scaleâ‰¦10.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Having received CPAP for obstructive sleep apnea prior to admission.&#xD;
&#xD;
          2. History of pneumothorax or brain surgery.&#xD;
&#xD;
          3. Coexisting heart failure or renal failure or persistent atrial fibrillation.&#xD;
&#xD;
          4. Unable to wear a nasal or nasal-oral mask.&#xD;
&#xD;
          5. Concomitant uncontrolled infection.&#xD;
&#xD;
          6. Swallowing difficulty or episodes of choking due to stroke&#xD;
&#xD;
          7. Coexisting central nervous diseases such as dementia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pei-Chen Lai, BD</last_name>
    <phone>8966-7000</phone>
    <phone_ext>1551</phone_ext>
    <email>sleepra01@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pei-Chen Lai</last_name>
      <phone>8966-7000</phone>
      <phone_ext>1551</phone_ext>
      <email>sleepra01@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>July 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Far Eastern Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Chou-Han Lin</investigator_full_name>
    <investigator_title>Principical investigator</investigator_title>
  </responsible_party>
  <keyword>obstructive sleep apnea</keyword>
  <keyword>stroke</keyword>
  <keyword>continuous positive airway pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

